| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: mulshinj{at}mail.nih.gov
Many arachidonic acid metabolites function in growth signaling for epithelial cells, and we previously reported the expression of the major arachidonic acid enzymes in human breast cancer cell lines. To evaluate the role of the 5-lipoxygenase (5-LO) pathway on breast cancer growth regulation, we exposed cells to insulinlike growth factor-1 or transferrin, which increased the levels of the 5-LO metabolite, 5(S)-hydrooxyeicosa-6E,8C,11Z,14Z-tetraenoic acid (5-HETE), by radioimmunoassay and high-performance liquid chromatography. Addition of 5-HETE to breast cancer cells resulted in growth stimulation, whereas selective biochemical inhibitors of 5-LO reduced the levels of 5-HETE and related metabolites. Application of 5-LO or 5-LO activating protein-directed inhibitors, but not a cyclooxygenase inhibitor, reduced growth, increased apoptosis, down-regulated bcl-2, up-regulated bax, and increased G1 arrest. Exposure of breast cancer cells to a 5-LO inhibitor up-regulated peroxisome proliferator-activated receptor (PPAR)a and PPARg expression, and these same cells were growth inhibited when exposed to relevant PPAR agonists. These results suggest that disruption of the 5-LO signaling pathway mediates growth arrest and apoptosis in breast cancer cells. Additional experiments suggest that this involves the interplay of several factors, including the loss of growth stimulation by 5-LO products, the induction of PPARg, and the potential activation of PPARg by interactions with shunted endoperoxides.
Key words: breast cancer · leukotrienes · 5-lipoxygenase pathway · peroxisome proliferator-activated receptor · apoptosis
This article has been cited by other articles:
|
|
 |
|
  C.-H. Jeong, A. M. Bode, A. Pugliese, Y.-Y. Cho, H.-G. Kim, J.-H. Shim, Y.-J. Jeon, H. Li, H. Jiang, and Z. Dong [6]-Gingerol Suppresses Colon Cancer Growth by Targeting Leukotriene A4 Hydrolase Cancer Res., July 1, 2009; 69(13): 5584 - 5591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Melstrom, D. J. Bentrem, M. R. Salabat, T. J. Kennedy, X.-Z. Ding, M. Strouch, S. M. Rao, R. C. Witt, C. A. Ternent, M. S. Talamonti, et al. Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model Clin. Cancer Res., October 15, 2008; 14(20): 6525 - 6530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, E. M. John, and S. A. Ingles 5-Lipoxygenase and 5-Lipoxygenase-Activating Protein Gene Polymorphisms, Dietary Linoleic Acid, and Risk for Breast Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2748 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mao, D. P. Tashkin, I-H. Tsu, and K. J. Serio Differential Modulation of Leukotriene B4 Synthesis and Degradation in Human Bronchoalveolar Lavage Cells by Lipopolysaccharide and Tobacco Smoke Cancer Prevention Research, September 1, 2008; 1(4): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tavolari, M. Bonafe, M. Marini, C. Ferreri, G. Bartolini, E. Brighenti, S. Manara, V. Tomasi, S. Laufer, and T. Guarnieri Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade Carcinogenesis, February 1, 2008; 29(2): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Newman, G. A. Kaysen, B. D. Hammock, and G. C. Shearer Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat J. Lipid Res., August 1, 2007; 48(8): 1792 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Mayburd, A. Martlinez, D. Sackett, H. Liu, J. Shih, J. Tauler, I. Avis, and J. L. Mulshine Ingenuity Network-Assisted Transcription Profiling: Identification of a New Pharmacologic Mechanism for MK886. Clin. Cancer Res., March 15, 2006; 12(6): 1820 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Avis, A. Martinez, J. Tauler, E. Zudaire, A. Mayburd, R. Abu-Ghazaleh, F. Ondrey, and J. L. Mulshine Inhibitors of the Arachidonic Acid Pathway and Peroxisome Proliferator-Activated Receptor Ligands Have Superadditive Effects on Lung Cancer Growth Inhibition Cancer Res., May 15, 2005; 65(10): 4181 - 4190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoque, S. M. Lippman, T.-T. Wu, Y. Xu, Z. D. Liang, S. Swisher, H. Zhang, L. Cao, J. A. Ajani, and X.-c. Xu Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention Carcinogenesis, April 1, 2005; 26(4): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Jiang, J. Wong, H. Fyrst, J. D. Saba, and B. N. Ames {gamma}-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis PNAS, December 21, 2004; 101(51): 17825 - 17830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Utomo, X. Jiang, S. Furuta, J. Yun, D. S. Levin, Y.-C. J. Wang, K. V. Desai, J. E. Green, P.-L. Chen, and W.-H. Lee Identification of a Novel Putative Non-selenocysteine Containing Phospholipid Hydroperoxide Glutathione Peroxidase (NPGPx) Essential for Alleviating Oxidative Stress Generated from Polyunsaturated Fatty Acids in Breast Cancer Cells J. Biol. Chem., October 15, 2004; 279(42): 43522 - 43529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Mao, I-H. Tsu, S. M. Dubinett, B. Adams, T. Sarafian, F. Baratelli, M. D. Roth, and K. J. Serio Modulation of Pulmonary Leukotriene B4 Production by Cyclooxygenase-2 Inhibitors and Lipopolysaccharide Clin. Cancer Res., October 15, 2004; 10(20): 6872 - 6878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. ROMANO and J. CLARIA Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy FASEB J, November 1, 2003; 17(14): 1986 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Anderson, W. Alrefai, P. Bonomi, T. M. Seed, P. Dudeja, Y. Hu, and J. E. Harris Caspase-Dependent and -Independent Panc-1 Cell Death Due to Actinomycin D and MK 886 Are Additive but Increase Clonogenic Survival Experimental Biology and Medicine, September 1, 2003; 228(8): 915 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wu, H. H. X. Xia, S. P. Tu, D. M. Fan, M. C. M. Lin, H. F. Kung, S. K. Lam, and B. C. Y. Wong 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer Carcinogenesis, February 1, 2003; 24(2): 243 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Liu, A. Nilsson, S. Oredsson, V. Badmaev, W.-Z. Zhao, and R.-D. Duan Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells Carcinogenesis, December 1, 2002; 23(12): 2087 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-G. Tong, X.-Z. Ding, R. C. Witt, and T. E. Adrian Lipoxygenase Inhibitors Attenuate Growth of Human Pancreatic Cancer Xenografts and Induce Apoptosis through the Mitochondrial Pathway Mol. Cancer Ther., September 1, 2002; 1(11): 929 - 935. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
